This knowledge could help researchers design new diagnostics, evaluate the healing powers of convalescent plasma, develop new therapeutic treatments, and importantly help design future vaccines or monoclonal antibody therapies capable of protecting against mutations that may occur in the COVID-19 virus. The findings could help explain the widely varying reactions COVID-19 patients have to the disease.
Study offers a differentiated patient-specific solution in minimal residual disease testing
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
Analysis of DNA shed into a patient s blood stream can provide a noninvasive means of detecting the presence of a tumor. Patients who have undergone initial treatment may only have small amounts of tumor DNA in their blood, which can be difficult to detect with conventional technology. TARDIS was developed to be highly sensitive and customizable for each patient, including those with only a trace amount of tumor remaining following surgery or other localized treat
Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test
News provided by
Share this article
Share this article
PHOENIX, Jan. 15, 2021 /PRNewswire/ Ashion Analytics LLC, a CLIA-certified and CAP-accredited clinical laboratory announced today that they will present data at the 2021 American Society for Clinical Oncology Gastrointestinal (ASCO GI) virtual meeting.
Abstract #109
Title:
Genomic profiling of gastrointestinal cancers by comprehensive tumor-normal sequencing
Authors: Fadel S. Alyaqoub, Pawan Noel, Szabolcs Szelinger, Thanemozhi G. Natarajan, Susan M. Dombrowski, Audrey A. Ozols, Laurie J. Goodman, Janine LoBello, Thomas Royce, Gargi D. Basu
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.